MentionFox
Home › funding signals › CNS Pharmaceuticals, Inc.
Form D · on the record

CNS Pharmaceuticals — $22.52M Form D filing, May 2026

CNS Pharmaceuticals, Inc. filed a Form D with the Securities and Exchange Commission on 2026-05-19.

CNS Pharmaceuticals, Inc. filed a Form D notice of an exempt securities offering with the SEC on May 19, 2026. The filing reports $22.52M sold. Its industry group is Pharmaceuticals. It names Rami Levin (Executive Officer, Director), Steve O'Loughlin (Executive Officer), Faith Charles (Director) (SEC Form D, May 19, 2026).

125 companies raised this week.

Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.

Andersen Aggregator LLC$1.9BBusiness services
AT Umbrella LLC$1.9BBusiness services
Legora, Inc.$221MAI and software
MD INVESTMENT LLC$169MBusiness services
Serval Inc.$149MAI and software
Check one company free

3 more Pharmaceuticals raises in Texas within 90 days ↓

Is this your company?

Key facts

Run the free check on CNS Pharmaceuticals, Inc. →

Sell to companies like CNS Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

CNS Pharmaceuticals, Inc.

New Form D on file · 2026-05-19 · the record

$22.52M
raise on the record
D
filing
13
investors in
TEXAS
based
Open the record →

What the record says

FilingForm D
Filed2026-05-19
Industry groupPharmaceuticals
Entity typeCorporation
Incorporated inNEVADA
BasedHOUSTON, TEXAS
CIK1729427
Accession0001683168-26-004126

Pitching, partnering or investing alongside them? See who really runs and owns CNS Pharmaceuticals, Inc.

Free to see. No signup.

Keep reading

More on the people and the money behind CNS Pharmaceuticals, Inc., from the filings we hold.

More raises like this

Pharmaceuticals raises by companies based in Texas, filed within 90 days of this one, largest first.

What do you want to do with CNS Pharmaceuticals, Inc.?

Get the full cited report on CNS Pharmaceuticals, Inc.

What the filing shows about CNS Pharmaceuticals, Inc.

  • 13 investors had already put money in when it filed.
  • The filing names 7 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on CNS Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

Who the filing names, and in what role

The filing gives CNS Pharmaceuticals, Inc.'s address as 2100 West Loop South, Suite 900, Houston, TX 77027.

What the filing says

  • Offered: $22,525,000. Sold: $22,525,000. Left to sell: nothing, all of it is sold. (filing)
  • Investors: 13 had already invested. (filing)
  • Date of first sale: May 4, 2026. (filing)
  • Types of securities: Equity; Options, warrants or other rights to acquire another security. (filing)
  • Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. (filing)
  • On sales commissions and finders' fees: the filing adds “Cash payment equal to 7.0% of gross proceeds, plus up to $75,000 reimbursement for fees and expenses and $15,000 for non-accountable expenses.” (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on CNS Pharmaceuticals, Inc. See pricing

Is CNS Pharmaceuticals, Inc. a real, registered company?

CNS Pharmaceuticals, Inc. is a registered filer with the SEC (CIK 1729427) and has filed since 2026-05-19. 1 filing is on record, the latest on 2026-05-19.

A filing shows the company exists and what it reports about itself. It is not an audit or a rating.

Who runs CNS Pharmaceuticals, Inc.?

CNS Pharmaceuticals, Inc.'s Form D of 2026-05-19 names Rami Levin, Steve O'Loughlin, Faith Charles and 4 more as its officers, directors or promoters.

How much has CNS Pharmaceuticals, Inc. raised?

Its new offerings report $22.52M sold across 1 offering, as its own filings state.

Pharmaceuticals · by week
This raise, $22.52M, filed week of May 18

Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $22.52M, on the same scale — one filing against the whole group's total, so it sits low by construction.

Want the whole picture on CNS Pharmaceuticals, Inc.?

What the filing shows about CNS Pharmaceuticals, Inc.

  • 13 investors had already put money in when it filed.
  • The filing names 7 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on CNS Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on CNS Pharmaceuticals, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    2 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind CNS Pharmaceuticals, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.

Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (cnspharma.com).

RSS

Tools for this story

Each opens in a new tab, filled in for CNS Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.

On these startup lists

Healthcare and health tech startups Biotech startups

Share this page

Is this your company?

Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.

CNS Pharmaceuticals, Inc.: Raised $22.52M, Form D filed 2026-05-19
Share on LinkedIn Share on X Download image

Cite this page

Permanent URL: https://mentionfox.com/funding/cns-pharmaceuticals-inc-form-d-26000001
Last updated 2026-10-20
Primary record: SEC filing 1 · SEC filing 2
CNS Pharmaceuticals raised $22.52M — SEC Form D filing, May 2026. MentionFox, 2026-10-20. https://mentionfox.com/funding/cns-pharmaceuticals-inc-form-d-26000001